Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: World J Urol. 2018 Sep 6;37(12):2623–2629. doi: 10.1007/s00345-018-2477-2

Figure 1.

Figure 1.

The effect of stereotactic ablative radiotherapy on clinical progression in men with oligometastatic prostate cancer. (A) Local progression-free survival of the entire cohort (blue), HSPC [34] and CRPC (green). (B) Biochemical progression-free survival of the entire cohort (blue), HSPC [34] and CRPC (green). (C) Distant progression-free survival of the entire cohort (blue), HSPC [34] and CRPC (green).